Company · Elkhart, Indiana, United States
Bayer Inc.
Everything this company holds in Health Canada’s product databases, as the company’s name is spelled there.
- Drug products (DIN)
- 304
- 128 authorized now
- Natural health products
- 129
- 71 active licences
- Medical device licences
- 15
- 10 active
- Notices of Compliance
- 401
Drug products
Authorized products first.
Showing 300 of 304 drug products. For the rest, search Health Canada’s database.
Natural health products
Active licences first, newest first.
Medical device licences
Active licences first, newest first.
| Name | Licence | Status | First licensed |
|---|---|---|---|
| HYDRASENSE VITAPRO | 113336 | Issued (active) · Class 2 | |
| HYDRASENSE DUAL ACTION | 111651 | Issued (active) · Class 2 | |
| HYDRASENSE KIDS FOR DRY EYES | 108794 | Issued (active) · Class 2 | |
| CLARITIN ALLERGY EYE DROPS | 108653 | Issued (active) · Class 2 | |
| HYDRASENSE COMPLETE | 107602 | Issued (active) · Class 2 | |
| HYDRASENSE ULTRA | 105231 | Issued (active) · Class 2 | |
| HYDRASENSE ALLERGY COMPLETE | 100196 | Issued (active) · Class 2 | |
| HYDRASENSE FOR DRY EYES | 98856 | Issued (active) · Class 2 | |
| HYDRASENSE ADVANCED | 98857 | Issued (active) · Class 2 | |
| HYDRASENSE ULTRA NIGHT | 98811 | Issued (active) · Class 2 | |
| DR. SCHOLL'S DUAL ACTION FREEZE AWAY WART REMOVER | 94792 | Discontinued at renewal · Class 2 | |
| DR. SCHOLL'S SKIN TAG REMOVER | 94793 | Discontinued at renewal · Class 2 | |
| DR.SCHOLL'S FREEZE AWAY WART REMOVER | 94794 | Discontinued at renewal · Class 2 | |
| INTRAUTERINE DEVICE NOVA-T | 13671 | Discontinued at renewal · Class 3 | |
| DISCOFIX-3 STOPCOCK | 1006 | Discontinued at renewal · Class 2 |
Notices of Compliance
Newest first.
- ADEMPASSeptember 14, 2026 · NOC 38282 · Supplement to a New Drug Submission (SNDS)
- VITRAKVIAugust 26, 2026 · NOC 38191 · Supplement to a New Drug Submission (SNDS)
- KOVALTRYAugust 25, 2026 · NOC 38169 · Supplement to a New Drug Submission (SNDS)
- LYNKUETAugust 12, 2026 · NOC 38111 · Supplement to a New Drug Submission (SNDS)
- NUBEQAJuly 30, 2026 · NOC 38029 · Supplement to a New Drug Submission (SNDS)
- AMBELVISTJuly 29, 2026 · NOC 38008 · New Drug Submission (NDS)
- MAGNEVISTMay 29, 2026 · NOC 37652 · Supplement to a New Drug Submission (SNDS)
- EYLEA HDMay 25, 2026 · NOC 37601 · Supplement to a New Drug Submission (SNDS)
- PRIMOVISTApril 24, 2026 · NOC 37400 · Supplement to a New Drug Submission (SNDS)
- HYRNUOJanuary 29, 2026 · NOC 36802 · New Drug Submission (NDS)
- CANESORAL; CANESORAL COMBI 1 DAYJanuary 20, 2026 · NOC 36750 · Supplement to a New Drug Submission (SNDS)
- KERENDIAJanuary 19, 2026 · NOC 36751 · Supplement to a New Drug Submission (SNDS)
- CLIMARA 25; CLIMARA 50; CLIMARA 75December 9, 2025 · NOC 36506 · Supplement to a New Drug Submission (SNDS)
- NUBEQANovember 25, 2025 · NOC 36428 · Supplement to a New Drug Submission (SNDS)
- STIVARGANovember 13, 2025 · NOC 36362 · Supplement to a New Drug Submission (SNDS)
- ALEVE NIGHTTIMEOctober 31, 2025 · NOC 36291 · Supplement to a New Drug Submission (SNDS)
- MAXIDOL LIQUID GELSOctober 31, 2025 · NOC 36293 · Supplement to a New Drug Submission (SNDS)
- ALEVE BACK AND BODY PAIN; ALEVE CAPLETS; ALEVE LIQUID GELSOctober 31, 2025 · NOC 36294 · Supplement to a New Drug Submission (SNDS)
- CIPRO ORAL SUSPENSIONOctober 23, 2025 · NOC 36244 · Supplement to a New Drug Submission (SNDS)
- JIVIOctober 20, 2025 · NOC 36206 · Supplement to a New Drug Submission (SNDS)
- XARELTOSeptember 23, 2025 · NOC 36051 · Supplement to a New Drug Submission (SNDS)
- ALEVE NIGHTTIMESeptember 19, 2025 · NOC 36030 · Supplement to a New Drug Submission (SNDS)
- ALEVE BACK AND BODY PAIN; ALEVE CAPLETS; ALEVE LIQUID GELSSeptember 12, 2025 · NOC 35993 · Supplement to a New Drug Submission (SNDS)
- MAGNEVISTSeptember 4, 2025 · NOC 35960 · Supplement to a New Drug Submission (SNDS)
- GADOVIST 1.0September 4, 2025 · NOC 35961 · Supplement to a New Drug Submission (SNDS)
- ULTRAVIST 300; ULTRAVIST 370August 27, 2025 · NOC 35911 · Supplement to a New Drug Submission (SNDS)
- NUBEQAAugust 18, 2025 · NOC 35859 · Supplement to a New Drug Submission (SNDS)
- STIVARGAAugust 8, 2025 · NOC 35811 · Supplement to a New Drug Submission (SNDS)
- MIRENAJuly 30, 2025 · NOC 35767 · Supplement to a New Drug Submission (SNDS)
- MAXIDOL LIQUID GELSJuly 24, 2025 · NOC 35739 · Supplement to a New Drug Submission (SNDS)
- LYNKUETJuly 23, 2025 · NOC 35723 · New Drug Submission (NDS)
- NUBEQAJuly 10, 2025 · NOC 35658 · Supplement to a New Drug Submission (SNDS)
- YAZ PLUSJuly 8, 2025 · NOC 35638 · Supplement to a New Drug Submission (SNDS)
- YAZJuly 7, 2025 · NOC 35641 · Supplement to a New Drug Submission (SNDS)
- TRIQUILAR 21; TRIQUILAR 28July 7, 2025 · NOC 35642 · Supplement to a New Drug Submission (SNDS)
- YASMIN 21July 7, 2025 · NOC 35643 · Supplement to a New Drug Submission (SNDS)
- NEXAVARJune 5, 2025 · NOC 35481 · Supplement to a New Drug Submission (SNDS)
- MIRENAMay 27, 2025 · NOC 35426 · Supplement to a New Drug Submission (SNDS)
- EYLEAMay 2, 2025 · NOC 35304 · Supplement to a New Drug Submission (SNDS)
- PRIMOVISTApril 16, 2025 · NOC 35218 · Supplement to a New Drug Submission (SNDS)
- GADOVIST 1.0April 16, 2025 · NOC 35219 · Supplement to a New Drug Submission (SNDS)
- EYLEA; EYLEA HDApril 14, 2025 · NOC 35194 · Supplement to a New Drug Submission (SNDS)
- EYLEA HDMarch 3, 2025 · NOC 34947 · Supplement to a New Drug Submission (SNDS)
- AERIUS KIDSJanuary 22, 2025 · NOC 34737 · Supplement to a New Drug Submission (SNDS)
- EYLEA HDJanuary 20, 2025 · NOC 34709 · Supplement to a New Drug Submission (SNDS)
- ULTRAVIST 300; ULTRAVIST 370January 14, 2025 · NOC 34687 · Supplement to a New Drug Submission (SNDS)
- KERENDIAJanuary 9, 2025 · NOC 34683 · Supplement to a New Drug Submission (SNDS)
- NUBEQADecember 27, 2024 · NOC 34625 · Supplement to a New Drug Submission (SNDS)
- JIVIOctober 11, 2024 · NOC 34177 · Supplement to a New Drug Submission (SNDS)
- CIPRO ORAL SUSPENSIONSeptember 12, 2024 · NOC 34027 · Supplement to a New Drug Submission (SNDS)
- EYLEASeptember 5, 2024 · NOC 33963 · Supplement to a New Drug Submission (SNDS)
- VITRAKVISeptember 3, 2024 · NOC 33923 · Supplement to a New Drug Submission (SNDS)
- NEXAVARAugust 26, 2024 · NOC 33868 · Supplement to a New Drug Submission (SNDS)
- ASPIRIN 81MG; ASPIRIN 81MG QUICK CHEWS; ASPIRIN EXTRA STRENGTH; ASPIRIN REGULAR STRENGTHJuly 15, 2024 · NOC 33631 · Supplement to a New Drug Submission (SNDS)
- ALEVE CAPLETSJuly 5, 2024 · NOC 33582 · Supplement to a New Drug Submission (SNDS)
- GADOVIST 1.0June 25, 2024 · NOC 33500 · Supplement to a New Drug Submission (SNDS)
- PRIMOVISTJune 14, 2024 · NOC 33457 · Supplement to a New Drug Submission (SNDS)
- MAGNEVISTJune 14, 2024 · NOC 33464 · Supplement to a New Drug Submission (SNDS)
- GADOVIST 1.0June 11, 2024 · NOC 33430 · Supplement to a New Drug Submission (SNDS)
- NUBEQAJune 10, 2024 · NOC 33416 · Supplement to a New Drug Submission (SNDS)
- CANESTEN COMBI 1 DAY SOFT CAPSULE + EXTRA STRENGTH EXTERNAL CREAM; CANESTEN SOFT CAPSULE 1April 25, 2024 · NOC 33141 · Supplement to a New Drug Submission (SNDS)
- XARELTOMarch 27, 2024 · NOC 32971 · Supplement to a New Drug Submission (SNDS)
- AERIUS SINUS + ALLERGYFebruary 29, 2024 · NOC 32797 · Supplement to a New Drug Submission (SNDS)
- MIRENAFebruary 20, 2024 · NOC 32730 · Supplement to a New Drug Submission (SNDS)
- XOFIGOFebruary 19, 2024 · NOC 32736 · Supplement to a New Drug Submission (SNDS)
- EYLEA HDFebruary 2, 2024 · NOC 32638 · Supplement to a New Drug Submission (SNDS)
- ALEVE NIGHTTIMEJanuary 31, 2024 · NOC 32621 · Supplement to a New Drug Submission (SNDS)
- ALEVE BACK AND BODY PAIN; ALEVE CAPLETS; ALEVE LIQUID GELSDecember 22, 2023 · NOC 32968 · Supplement to a New Drug Submission (SNDS)
- NUBEQANovember 22, 2023 · NOC 32163 · Supplement to a New Drug Submission (SNDS)
- BILTRICIDENovember 17, 2023 · NOC 32130 · Supplement to a New Drug Submission (SNDS)
- CANESTEN COMBI 1 DAY COMFORTAB + EXTRA STRENGTH EXTERNAL CREAMOctober 6, 2023 · NOC 31803 · Supplement to a New Drug Submission (SNDS)
- VITRAKVIAugust 18, 2023 · NOC 31450 · Supplement to a New Drug Submission (SNDS)
- JIVIAugust 3, 2023 · NOC 31365 · Supplement to a New Drug Submission (SNDS)
- ADALAT XLJune 30, 2023 · NOC 31090 · Supplement to a New Drug Submission (SNDS)
- EYLEAJune 29, 2023 · NOC 31089 · Supplement to a New Drug Submission (SNDS)
- EYLEAJune 29, 2023 · NOC 31091 · Supplement to a New Drug Submission (SNDS)
- VERQUVOApril 28, 2023 · NOC 30582 · New Drug Submission (NDS)
- XARELTOApril 18, 2023 · NOC 30569 · Supplement to a New Drug Submission (SNDS)
- BETASERONApril 4, 2023 · NOC 30484 · Supplement to a New Drug Submission (SNDS)
- VITRAKVIMarch 29, 2023 · NOC 30414 · Supplement to a New Drug Submission (SNDS)
- KOVALTRYMarch 7, 2023 · NOC 30265 · Supplement to a New Drug Submission (SNDS)
- BETASERONDecember 20, 2022 · NOC 29741 · Supplement to a New Drug Submission (SNDS)
- ADALAT XLDecember 13, 2022 · NOC 29697 · Supplement to a New Drug Submission (SNDS)
- CLARITIN ALLERGY + SINUS; CLARITIN ALLERGY + SINUS EXTRA STRENGTHNovember 29, 2022 · NOC 29582 · Supplement to a New Drug Submission (SNDS)
- EYLEANovember 10, 2022 · NOC 29449 · Supplement to a New Drug Submission (SNDS)
- AERIUS; AERIUS KIDSNovember 2, 2022 · NOC 29362 · Supplement to a New Drug Submission (SNDS)
- KERENDIAOctober 14, 2022 · NOC 29218 · New Drug Submission (NDS)
- ADEMPASOctober 13, 2022 · NOC 29211 · Supplement to a New Drug Submission (SNDS)
- NUBEQASeptember 29, 2022 · NOC 29122 · Supplement to a New Drug Submission (SNDS)
- NEXAVARSeptember 28, 2022 · NOC 29090 · Supplement to a New Drug Submission (SNDS)
- MIRENASeptember 26, 2022 · NOC 29089 · Supplement to a New Drug Submission (SNDS)
- ULTRAVIST 300; ULTRAVIST 370March 25, 2022 · NOC 27830 · Supplement to a New Drug Submission (SNDS)
- RIVAROXABANMarch 24, 2022 · NOC 27837 · Supplement to a New Drug Submission (SNDS)
- CANESTEN 1 DAY INTERNAL CREAM; CANESTEN 3 DAY INTERNAL CREAM; CANESTEN 6 DAY INTERNAL CREAM; CANESTEN COMBI 1 DAY; CANESTEN COMBI 1 DAY INTERNAL + EXTERNAL CREAMS; CANESTEN COMBI 3 DAY; CANESTEN EXTERNAL ANTIFUNGAL CREAM; CANESTEN EXTRA STRENGTH EXTERNAL ANTIFUNGAL CREAMFebruary 10, 2022 · NOC 27563 · Supplement to a New Drug Submission (SNDS)
- CANESORAL; CANESORAL COMBI; CANESORAL COMBI 1 DAYFebruary 10, 2022 · NOC 27564 · Supplement to a New Drug Submission (SNDS)
- CANESTEN 1% TOPICAL CREAMFebruary 10, 2022 · NOC 27566 · Supplement to a New Drug Submission (SNDS)
- EYLEAFebruary 10, 2022 · NOC 27598 · Supplement to a New Drug Submission (SNDS)
- VITRAKVIJanuary 26, 2022 · NOC 27485 · Supplement to an Abbreviated New Drug Submission (SANDS)
- KOVALTRYJanuary 19, 2022 · NOC 27426 · Supplement to a New Drug Submission (SNDS)
- XARELTODecember 3, 2021 · NOC 27177 · Supplement to a New Drug Submission (SNDS)
The latest 100 of 401.
Recalls and safety alerts that mention its products
Health Canada’s recall notices do not carry licence numbers, so these are matched by name. A notice may cover another product or only some lots: read it to see what it covers.
- Hydrasense Baby Nasal Care EasydoseMay 2, 2024 · Ear, nose and throat · Sterility · Type I
- Claritin® Rapid Dissolve 10 mg: Potential contaminationDecember 20, 2023 · Drugs · Contamination · Type III
- Claritin® Kids Rapid Dissolve 5 mg: Potential contaminationDecember 20, 2023 · Drugs · Contamination · Type II
- Vitrakvi: Presence of contamination in affected lotNovember 8, 2023 · Drugs · Contamination · Type II
- Certain lots of Tinactin aerosol sprays for athlete’s foot recalledOctober 5, 2021 · Drugs
- XARELTO (rivaroxaban) - Increase in all-cause mortality, thromboembolic and bleeding events in patients after transcatheter aortic valve replacementDecember 20, 2018 · Drugs · Product safety
- XOFIGO® (radium Ra 223 dichloride) - Increased Incidence of Fractures and Trend for Increased Deaths with XOFIGO used in combination with abiraterone and prednisone/prednisoloneNovember 8, 2018 · Biologic or vaccine · Product safety
- Aerius (2017-07-17)October 4, 2017 · Drugs · Product safety · Type III
- Claritin Rapid Dissolve (2017-07-17)October 4, 2017 · Drugs · Product safety · Type III
- Aerius Dual Action 12 Hour (2017-07-17)October 4, 2017 · Drugs · Product safety · Type III
- Claritin Rapid Dissolve (2017-07-17)October 4, 2017 · Drugs · Product safety · Type III
- RestoraLAX 30 + 7 Bonus Pack (2017-07-07)July 11, 2017 · Drugs · Product safety · Type I
- Bayer expands recall of RestoraLAX, sold nationwide, due to potential choking hazardJuly 8, 2017 · Drugs
- RestoraLAX 45 + 10 Value Pack (2017-07-02)July 6, 2017 · Drugs · Medical devices · Type I
- RestoraLAX 45 + 10 Value Pack sold at Costco Canada recalled due to potential choking hazardJuly 2, 2017 · Drugs
- ADEMPAS (riociguat) - New Contraindication for Patients with Pulmonary Hypertension Associated with Idiopathic Interstitial Pneumonias (PH-IIP)August 15, 2016 · Drugs · Product safety
- Kogenate FS (with Vial Adapter) (2016-07-25)July 27, 2016 · Drugs · Product safety · Type III
- Adalat XL (2014-09-02)September 29, 2014 · Drugs · Product safety · Type III
- Fluoroquinolone Antibiotics (AVELOX, CIPRO, CIPRO XL, and LEVAQUIN) – Worsening of Symptoms in Patients with Myasthenia Gravis – For the PublicMarch 14, 2012 · Drugs
- Fluoroquinolone Antibiotics (AVELOX, CIPRO, CIPRO XL, and LEVAQUIN) - Worsening of Symptoms in Patients with Myasthenia Gravis - For Health ProfessionalsMarch 9, 2012 · Drugs
- Yasmin and Yaz (drospirenone): Updated information on increased risk of blood clotsDecember 5, 2011 · Drugs · Product safety
- MIRENA (Levonorgestrel-Releasing Intrauterine System) - Potential Risk of Uterine Perforation - For Health ProfessionalsJune 17, 2010 · Drugs
- MIRENA (Levonorgestrel-Releasing Intrauterine System) - Potential Risk of Uterine Perforation - For the PublicJune 17, 2010 · Drugs
- Updated Labelling for Antibiotic Avelox (Moxifloxacin) Regarding Rare Risk of Severe Liver InjuryMarch 22, 2010 · Drugs
- Archived - Cialis (tadalafil), Levitra (vardenafil hydrochloride) and Viagra (sildenafil citrate) - Advisories, Warnings and Recalls for the PublicJune 28, 2006 · Drugs
- Cialis (tadalafil), Levitra (vardenafil hydrochloride) and Viagra (sildenafil citrate)June 28, 2006 · Drugs
- Archived - Market withdrawal of Baycol (cerivastatin) - Bayer Inc.August 8, 2001 · Drugs
- Archived - Cerivastatin (BAYCOL®) And Gemfibrozil - Increased Risk of Rhabdomyolysis - Concomitant Use ContraindicatedJuly 16, 2001 · Drugs